253 results about "Sesquiterpene" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

The invention discloses a phoebe zhennan PzGGPS12 gene and application of the phoebe zhennan PzGGPS12 gene to improvement of yield and drought tolerance of plant terpenoids, and belongs to the field of genetic engineering, a key enzyme gene PzGGPS12 for catalyzing biosynthesis of the terpenoids in phoebe zhennan wood is screened and analyzed, and a full-length CDS nucleic acid sequence of the PzGGPS12 is obtained. Transgenic experiments prove that overexpression of the gene improves the relative content of tobacco monoterpenes and triterpenes. Short-term drought experiments prove that overexpression of the gene can promote biosynthesis of sesquiterpenes, diterpenes and triterpenes so as to enhance drought tolerance of transgenic tobacco. Therefore, the gene can be introduced into a plant as a target gene, the yield of terpenoids in the plant is increased, and the drought tolerance of the plant is enhanced so as to improve the variety of the plant.

The invention discloses a marine streptomyces strain SHEa3, a compound derived from the marine streptomyces strain SHEa3 and application of the marine streptomyces strain SHEa3, the classification name of the marine streptomyces strain SHEa3 is Streptomyces sp, the preservation number of the marine streptomyces strain SHEa3 is GDMCC No: 66667, and the preservation date of the marine streptomyces strain SHEa3 is July 14, 2025. The invention also discloses a sesquiterpenoids compound streptaviol A derived from marine streptomyces and application of the sesquiterpenoids compound streptaviol A in preparation of drugs for preventing and treating vibrio diseases of mariculture animals. The invention further discloses application of the sesquiterpenoids, namely the sea threitol C, derived from the marine streptomyces in preparation of drugs for preventing and treating vibrio diseases of mariculture animals. The marine streptomyces source compound has efficient anti-vibrio activity, and the marine streptomyces source compound streptaviol A and the helithreitol C are used for preparing the medicine for preventing and treating vibrio diseases of mariculture animals, so that the side effect is low, and the activity is excellent.

The present invention relates to processes for the oxidation of sesquiterpenes comprising fused 5- and 7-membered rings using mutant Cytochrome P450 family 102A sub-family member (CYP102A) enzymes. The invention also relates to mutant CYP102A enzymes, polynucleotides encoding the enzymes, cells expressing the enzymes, transgenic animals or plants comprising the enzymes, and compounds produced by the processes.

The invention discloses a saccharomyces cerevisiae recombinant strain based on a uracil metabolism gene URA3 as well as a construction method and application of the saccharomyces cerevisiae recombinant strain. The construction method comprises the following steps: taking saccharomyces cerevisiae rich in farnesyl pyrophosphate as an original strain, introducing a uracil metabolism gene URA3, synchronously overexpressing a ribosome biosynthetic gene UTP10 and an iron metabolism gene FIT3, and utilizing the uracil metabolism gene URA3 to express up-regulation correlation with the ribosome biosynthetic gene UTP10 and the iron metabolism gene FIT3, so as to obtain the farnesyl pyrophosphate-rich saccharomyces cerevisiae. The metabolic flux of the terpenoids is enhanced, and the saccharomyces cerevisiae recombinant strain for efficiently producing the terpenoids is constructed. According to the method, a metabolic network of yeast is systematically optimized, and combined regulation and control on precursor flux distribution, protein translation capability and metal ion steady state are realized, so that the microbial synthesis efficiency of sesquiterpenoids such as patchouli alcohol and beta-elemene is remarkably improved.

The invention relates to the technical field of bioengineering, in particular to a saccharomyces cerevisiae engineering strain for producing caryophyllene and application of the saccharomyces cerevisiae engineering strain. The invention provides a saccharomyces cerevisiae engineering strain which has enhanced expression and / or activity of mevalonic acid pathway enzyme and one or more modifications selected from the following (1)-(2): (1) weakened expression and / or activity of sterol synthesis pathway enzyme; (2) attenuated expression and / or activity of fatty acid synthetic pathway enzymes; compared with an original strain, the saccharomyces cerevisiae engineering strain has the advantage that the sesquiterpene yield is increased. Compared with an original strain, the saccharomyces cerevisiae engineering strain has the advantages that the production capacity of the sesquiterpenes such as the caryophyllene is obviously improved, the sesquiterpenes such as the caryophyllene can be efficiently synthesized, and the saccharomyces cerevisiae engineering strain has better application value.

The invention discloses a cadinane type sesquiterpene as well as a preparation method and application thereof. The cadinane type sesquiterpene is separated from cinnamon bark, and has at least one of structural formulas shown as a formula (I), a formula (II), a formula (III) and a formula (IV). Liver protection activity evaluation is carried out by applying an alcohol-induced hepatocyte injury model, and it is found that the cadinane type sesquiterpene can effectively relieve alcohol-induced AML-12 hepatocyte injury; the dumarane sesquiterpenes can inhibit the alcoholic liver disease and relieve fat accumulation, so that the dumarane sesquiterpenes have the anti-alcoholic liver disease activity, can be applied to preparation of the anti-alcoholic liver disease drugs, and have good research and development prospects; belongs to the field of natural medicinal chemistry.

The invention discloses a biosynthetic gene cluster of a novel skeleton sesquiterpenoid (sestercyclic acid) and an application of the biosynthetic gene cluster of the novel skeleton sestercyclic acid (sestercyclic acid). The sesterterpene tercyclic acid biosynthetic gene cluster at least comprises three genes, namely, terA, terB and terC, and the nucleotide sequences of the sesterterpene tercyclic acid biosynthetic gene cluster are as shown in SEQ ID NO.1-3. The gene cluster of the terrecyclic acid compound disclosed by the invention is found for the first time, and each gene function is also confirmed for the first time. Protease TerA catalyzes farnesyl pyrophosphate (FPP) to be cyclized into a new skeleton sesquiterpene 25, then P450 protease TerB is oxidized into a compound 32, and the compound 32 is dehydrogenated through protease TerC to form a final product compound 2. According to the present invention, the effective drug source approach is provided for the development of the terrecyclic acid antitumor compound.

The application belongs to the technical field of microorganisms and particularly relates to a kind of Aspergillus ustus and application thereof.The Aspergillus ustus is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.40820.The Aspergillus ustus can be separated to obtain sesquiterpenes shown in formula I and formula II, and the sesquiterpenes have good bacteriostatic activity on Physarum polycephalum, and the bacteriostatic rates are 79.45% and 76.71% respectively at a final concentration of 100 μg / mL, which is equivalent to the control agent of bercyn in inhibiting mycelial growth.

This invention discloses a genetic transformation and gene editing method applicable to multiple sesquiterpene species, belonging to the field of plant genetic transformation and gene editing technology. The method uses the cotyledonary nodes of sterile seedlings of the sesquiterpene genus as explants, and introduces an optimized pScEF1α-Cas9 gene editing transformation vector using Agrobacterium infection. Regenerated plants are obtained through recovery culture, selection culture, and rooting culture. The vector contains four gene expression units: pScEF1α:Cas9, pGmU6:sgRNA, pGmUBI:DsRed2, and pCaMV35S:HygR. In vivo screening is further performed using the DsRed2 fluorescent reporter gene, and the gene-edited plants are identified by molecular detection. This method is applicable to common sesquiterpene, stem-nodled sesquiterpene, and spiny sesquiterpene, and has advantages such as strong species versatility, high transformation efficiency, short cycle, visualized screening, and high positive rate, providing efficient technical support for gene function research and genetic improvement of sesquiterpene species.

The invention discloses curcuma wenyujin sesquiterpene synthase CwTPS8 as well as a coding gene and application thereof, and belongs to the technical field of plant genetic engineering, the amino acid sequence of the curcuma wenyujin sesquiterpene synthase CwTPS8 is shown as SEQ ID NO.1, the nucleotide sequence of the gene for coding the curcuma wenyujin sesquiterpene synthase CwTPS8 is shown as SEQ ID NO.2, and the nucleotide sequence of the gene for coding the curcuma wenyujin sesquiterpene synthase CwTPS8 is shown as SEQ ID NO.1. The curcuma wenyujin sesquiterpene synthase CwTPS8 can be used for preparing beta-caryophyllene, alpha-humulene and other curcuma wenyujin sesquiterpenoids by taking farnesyl pyrophosphate FPP as a substrate, and the technology can be used for subsequently producing the sesquiterpenoids through a microbial cell factory. Meanwhile, a foundation is laid for heterologous synthesis and further development and utilization of sesquiterpenoids such as beta-caryophyllene and alpha-humulene.

The application relates to application of a sesquiterpenoid compound in preparation of a medicine for preventing and / or treating pulmonary fibrosis. The sesquiterpenoid compound has obvious inhibiting collagen deposition effect on TGF-beta 1 induced human embryo lung fibroblasts, does not show cytotoxicity, has good anti-pulmonary fibrosis activity, and can be used for preparing the medicine for preventing and / or treating pulmonary fibrosis.

The invention relates to a recombinant genetically engineered bacterium for synthesizing terpenoids. The recombinant genetically engineered bacterium is saccharomyces cerevisiae in which a gal80 gene, an lpp1 gene and a dpp1 gene are knocked out and a heterologous MVA pathway gene and an AuoblA gene are integrated. According to the invention, a ophiobollin synthesis route is introduced into the saccharomyces cerevisiae in a heterologous manner for the first time, so that de novo synthesis of a ophiobollin skeleton compound, namely the ophiobollin F and an oxidation product of the ophiobollin F is realized; the synthesis of the ophiobolin F of 5.1 g / L is realized, which is also the highest sesterterpene heterologous synthesis yield reported at present; according to the invention, the ophiobolin 5-OH-21-CHO-opF with a new structure, which has excellent anti-cancer activity, is obtained through identification; the engineering strain of high-yield ophiobolin U is constructed, and the shake flask yield reaches 128.9 mg / L.

The present invention refers to a method for the preparation of a compound according to formula (45), its enantiomers, diastereomers, a racemic mixture, and the pharmaceutically acceptable salts thereof. Furthermore the invention refers to a compound of formula (45) prepared by said method for use in treatment of neurodegenerative disorders and to pharmaceutical compositions.

The present invention discloses terpene compounds derived from polar fungi, their preparation methods and applications, and respectively provides a calamenane-type sesquiterpene compound eutyacorane and a pimarane-type diterpene compound libertellenone Z derived from polar fungi. The structures are shown in the following formulas I and II respectively: The experimental results show that the two compounds have a better inhibition rate on the release of NO in the LPS-induced inflammatory model of mouse macrophages RAW264.7, providing a new type of choice for anti-inflammatory drugs.

The application belongs to the field of enzyme genetic engineering, and particularly relates to application of a sesquiterpene synthase and a mutant thereof in synthesis of enantiomeric-drimenol compounds, wherein the sesquiterpene synthase is a sesquiterpene synthase from Chenopodium quinoa Willd., and includes CqDMDS1 or CqDMDS2; the mutant of the sesquiterpene synthase is a mutant CqDMDS1 in which an amino acid at position 443 of CqDMDS1 is mutated F443A / G The application realizes heterologous expression of the sesquiterpene synthase and the mutant thereof from Chenopodium quinoa Willd. in an Escherichia coli and a N. benthamiana expression system, catalyzes synthesis of (-)‑8,11-driman-diol or (+)‑drimenol. It is found through activity test that the sesquiterpene synthase from Chenopodium quinoa Willd. has a significant inhibitory effect on plant pathogenic fungi Phytophthora nicotianae, Phytophthora sojae and Fusarium graminearum. The sesquiterpene synthase and the mutant thereof and the biological preparation of the catalytic product have important significance for development of biological pesticides.

The invention belongs to the technical field of medicinal plant cultivation, and particularly provides a method for increasing the content of sesquiterpene glycoside in dendrobium nobile. The method comprises the step of applying a magnesium ion-containing solution with effective concentration at the growth stage of dendrobium nobile. Preferably, the magnesium ion-containing solution is a magnesium chloride solution, the application concentration is 10-500 mg / L, the magnesium ion-containing solution is applied in a foliage spraying or root irrigation mode, and the key period of application is the rapid growth period or the effective component accumulation period of the dendrobium nobile. The promotion effect of exogenous magnesium ions on biosynthesis of the sesquiterpene glycoside of the dendrobium nobile is disclosed for the first time, and the content of sesquiterpene glycoside components in the dendrobium nobile medicinal material can be remarkably increased under the condition that a basic cultivation mode is not changed, so that the medicinal potential and market value of immunoregulation, anti-inflammation and the like of the dendrobium nobile medicinal material are enhanced. The method is simple, efficient, low in cost, free of pollution and suitable for industrial application.

The invention relates to a sesquiterpenoid glycoside compound in Atractylodes lancea, and a preparation method and application thereof. The invention belongs to the technical field of medicines, and relates to a method for extracting and separating a sesquiterpenoid glycoside compound (1S, 5S, 7R, 10S)-10-hydroxy-deoxy split-ring atractylodes macrocephala delta-lactone-11-O-beta-D-glucopyranoside from rhizome of Atractylodes lancea by using normal phase silica gel, reverse phase silica gel, preparative high performance liquid chromatography and other technologies. In-vitro anti-tumor activity screening experiments show that the compound has good anti-tumor activity, including obvious inhibition effects on human lung cancer cells A549, human cervical cancer cells Hela and human liver cancer cells HepG-2. Therefore, the sesquiterpenoid glycoside compound has a prospect of being developed into antitumor drugs.

The invention provides a method for increasing the content of geranone and furandiene in zedoary turmeric oil, which comprises the following steps: activating secondary metabolism through moderate drought, low temperature or salt stress in a key growth period of zedoary turmeric, and promoting sesquiterpene accumulation; then, phosphorus-potassium fertilizer and zinc-boron trace elements are additionally applied, nitrogen fertilizer is reduced, and the component proportion is optimized; the preparation method comprises the following steps: washing, drying and crushing the rhizome of curcuma zedoary, adding water to infiltrate, extracting crude oil by water vapor, performing reduced pressure distillation and molecular distillation purification, finally filling nitrogen and sealing, and refrigerating at 2-4 DEG C and storing in a dark place. According to the method, the content and extraction rate of target components can be remarkably increased, purity is guaranteed, thermosensitive components are protected, pollution is reduced, and the storage period is prolonged.

The invention relates to the technical field of agriculture, and provides germacane type sesquiterpenoids in tithonia diversifolia as well as a preparation method and application thereof.The preparation method comprises the steps that stem and leaf parts of tithonia diversifolia are subjected to ethanol cold-soaking extraction, and an extracting solution is subjected to vacuum concentration to obtain a total extract; suspending the total extract with water, sequentially extracting with petroleum ether and ethyl acetate, and concentrating the extract liquor under reduced pressure to obtain each extraction layer; carrying out silica gel column chromatography separation on the ethyl acetate extraction layer, and combining to obtain six parts A-F; carrying out MCI column chromatography separation on the part D, and combining to obtain thirteen parts D1-D13; carrying out silica gel column chromatography separation on the D9 part, and combining to obtain fifteen parts D91-D915; and separating the D915 part by adopting HPLC (High Performance Liquid Chromatography) to prepare two germacane type sesquiterpenoids. The preparation method disclosed by the invention is simple and good in reproducibility, and the prepared germacane type sesquiterpenoids are high in purity and have specific herbicidal activity on foreign invasive plants such as ambrosia trifida and ambrosia esculenta.

The application belongs to the technical field of biology, and discloses application of CmPHL1 transcription factor in inhibition of citrus leaf oil cell formation and regulation of volatile substances. In view of the problem of insufficient research on existing citrus oil cell formation and essential oil synthesis, a pGBI-CmPHL1 overexpression vector is constructed, and positive strains are obtained by means of Agrobacterium-mediated transformation of citrus. Experiments prove that overexpression of CmPHL1 can significantly reduce the number of oil cells and the content of monoterpenes, sesquiterpenes and other volatile substances. CmPHL1 targets the molecular regulation network of oil cell development, accurately regulates and is heritable, provides a new gene target for citrus quality improvement and breeding, is in line with the direction of green agriculture, and has important economic and ecological benefits.

Sesterterpenoid compounds and an extract L01 of Leucosceptrum canum, and use thereof in treatment of psoriasis are provided, belonging to the technical field of natural medicinal chemistry. The sesterterpenoid compound of the Leucosceptrum canum has a structure shown in any one of Formulas 9 to 12, which shows a highly rare backbone type, exhibits anti-inflammatory and immunosuppressive activities, and can be used in preparation of an anti-inflammatory drug and an immunosuppressive drug. A Leucosceptrum canum extract L01 having compounds 1 to 12 as characteristic ingredients, and use thereof in preparation of an anti-inflammatory drug and an immunosuppressive drug are further provided.

This invention provides a method for the separation, purification, and aroma quality control of biosynthesized patchouli essential oil, belonging to the field of daily chemical product purification technology. It solves the technical problems of low separation efficiency, insufficient purity, easy destruction of heat-sensitive components, and low aroma matching in existing essential oils. This method uses metabolically engineered brewer's yeast fermentation broth as raw material, sequentially undergoing pretreatment, multi-stage countercurrent extraction, three-stage high-vacuum distillation, column chromatography purification, activated carbon decolorization and deodorization, aroma component recombination, and product stabilization to obtain high-purity patchouli essential oil with high aroma matching. This invention is adapted to the three-stage distillation process of biosynthetic systems, achieving efficient separation of solvents, sesquiterpenes, and patchouli alcohol, resulting in high purity; the product aroma has a high matching degree with natural Indonesian essential oils; the process is mild throughout, can be stably scaled up from small-scale to ton-scale, and is low-cost. This invention provides a complete, efficient, and green technical solution for the industrialization of natural fragrances derived from synthetic biology.

The invention provides a novel method for preparing an intermediate compound of aromatic sesquiterpenes Commiphoranes C-D. The method comprises the following steps: substituting the ortho-position of a compound 1 with iodine through n-butyllithium and diiodoethane to obtain a compound 2; removing methoxyl by using boron tribromide to obtain a compound 3; performing nucleophilic substitution on 3-allyl bromide and potassium carbonate to synthesize a compound 4; carrying out Grignard reaction to obtain a compound 5; oxidizing into a compound 6 through a Dess-Martin oxidizing agent; finally, (CH3Si) 3SiH and triethyl boron are subjected to intramolecular free radical series cyclization, so that synthesis of an aromatic sesquiterpene Commiphoranes C-D intermediate compound is successfully completed, sufficient preparation is made for follow-up total synthesis of the natural product, key intramolecular free radical series cyclization has the capacity of efficiently constructing a polycyclic system, and the synthesis process is simple and convenient. According to the preparation method, the defects of expensive reagents, long 14-step linear synthesis route, low yield and the like in the existing synthesis route are overcome; the popularization potential is high.

The application discloses a pterosin sesquiterpenoid compound and a preparation method and application thereof, belongs to the technical field of biological medicines, aims at the problems of a research blank of pterosin sesquiterpenoid compounds in Anemone raddeana and a lack of structure-confirmed anti-inflammatory active monomers, and provides a pterosin sesquiterpenoid compound with a structural formula as shown in the following.The compound preparation needs to first crush dried whole grass of Anemone raddeana, extract by heating and refluxing with an organic solution, concentrate under reduced pressure to obtain total extract; then, the extract is extracted by petroleum ether, ethyl acetate and n-butanol step by step, the ethyl acetate part extract is enriched, and the high-purity product is prepared through multi-step purification of a silica gel column, a C-18 reverse phase column, a gel column and semi-preparative liquid chromatography.In addition, the compound can dose-dependently inhibit the NO release of LPS-induced macrophages, and can be used for preparing anti-inflammatory drugs for treating or preventing inflammatory diseases related to excessive production of nitric oxide, fills the research blank, and provides a high-quality candidate component for anti-inflammatory drug research and development.

This invention discloses a eucalyptane-type sesquiterpene dimer compound, its preparation method, and its applications, belonging to the field of pharmaceutical preparation technology. The six eucalyptane-type sesquiterpene dimers (compounds 1-6) disclosed in this invention are novel compounds with defined stereostructures and optically pure composition, exhibiting varying degrees of cytotoxic activity against HepG2, Hep3B, and Huh7 cells. Using sorafenib as a positive control, compounds 1, 5, and 6 showed stronger cytotoxic activity against HepG2 cells than the positive control sorafenib, compound 5 exhibited the strongest cytotoxic activity against Hep3B cells, and compounds 1, 4, 5, and 6 showed stronger cytotoxic activity against Huh7 cells than the positive control sorafenib. Therefore, compounds 1-6 disclosed in this invention have the potential to be developed into anti-hepatocellular carcinoma drugs, showing promising application prospects, and also provide important theoretical support for the further development of Atractylodes macrocephala medicinal plant resources.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a sesquiterpene compound and / or its pharmaceutically acceptable salt in the preparation of medicaments for treating or preventing infectious diseases caused by Staphylococcus aureus, particularly in the preparation of medicaments for treating or preventing infectious diseases caused by drug-sensitive or drug-resistant Staphylococcus aureus. The structure of the sesquiterpene compound of this invention is shown in Formula I: [Formula I]. The sesquiterpene compound used in this invention is derived from *Chrysanthemum indicum*, which is widely available and has low production costs. This invention is the first to discover that the sesquiterpene compound shown in Formula I exhibits very good inhibitory activity against Staphylococcus aureus, including very good inhibitory activity against drug-sensitive, drug-neutral, or drug-resistant Staphylococcus aureus.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

The present invention relates to processes for the oxidation of sesquiterpenes comprising fused 5- and 7-membered rings using mutant Cytochrome P450 family 102A sub-family member (CYP102A) enzymes. The invention also relates to mutant CYP102A enzymes, polynucleotides encoding the enzymes, cells expressing the enzymes, transgenic animals or plants comprising the enzymes, and compounds produced by the processes.